Skip to main content

Desmopressin Clinical Prior Authorization Revision Scheduled for March 15, 2021

Last updated on 1/15/2021

On March 15, 2021, The Texas Health and Human Services Commission (HHSC) will revise the desmopressin clinical prior authorization by removing the hyponatremia denial criteria. The change will allow approval for people whose hyponatremia has been resolved.

The desmopressin clinical prior authorization is optional for managed care organizations (MCOs). The Pharmacy Clinical Prior Authorization Assistance Chart shows the prior authorization each MCO uses and how those authorizations relate to the authorizations used for traditional Medicaid claim processing. This chart is updated quarterly. Providers can also refer to the MCO Resources for links to each MCO's list of clinical prior authorizations. 

Email questions or comments to